Sector News

Pfizer inks manufacturing deal with Gilead for COVID-19 med remdesivir

August 11, 2020
Life sciences

Pfizer has inked a multi-year agreement with Gilead Sciences to manufacture and supply the investigational antiviral drug remdesivir for the treatment of COVID-19.

Under the terms of the agreement, Pfizer will provide contract manufacturing services at its McPherson, Kansas facility in the US to manufacture and supply remdesivir for Gilead.
Following the agreement, Pfizer has become one of multiple external manufacturing organisations supporting efforts to scale-up the supply of the promising investigational COVID-19 treatment.

The deal supports Pfizer five-point plan, launched in March, which called on all members of the ‘innovation ecosystem’ to commit to working together in addressing the COVID-19 pandemic.
That includes large pharmaceutical companies and smaller biotech companies, as well as government agencies and academic institutions.

“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions,” said Albert Bourla, Chairman and Chief Executive Officer at Pfizer.
“Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic.
“In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible,” he added.

By: Lucy Parsons

Source: Pharma Times

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend